The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 19, 2017

Filed:

Jun. 17, 2014
Applicant:

Professional Compounding Centers of America (Pcca), Houston, TX (US);

Inventor:

Daniel Banov, Sugar Land, TX (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/14 (2006.01); A61K 31/496 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/4174 (2006.01); A61K 31/4196 (2006.01); A61K 31/506 (2006.01); A61K 31/513 (2006.01); A61K 31/5375 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 9/0073 (2013.01); A61K 9/146 (2013.01); A61K 31/137 (2013.01); A61K 31/4174 (2013.01); A61K 31/4196 (2013.01); A61K 31/506 (2013.01); A61K 31/513 (2013.01); A61K 31/5375 (2013.01);
Abstract

A pharmaceutical composition for the treatment of yeast and fungal infections is provided. The composition may include a micronized poloxamer composition as excipient and itraconazole as active pharmaceutical ingredient (API). The micronized poloxamer composition may include a combination of poloxamer 188 and poloxamer 407. Additionally, micronized poloxamer-based composition, used as a surfactant, may help to break out or disrupt the membrane of microorganisms' cells within biofilm, thus allowing APIs, such as itraconazole, to improve their action and effectiveness against fungus and yeast infections. Additionally, poloxamer-based composition may be delivered to the infected site by different administration routes, such as orally, topically, via nasal, lung inhalation, and transdermal delivery. Due to the synergistic effect of poloxamer-based composition, itraconazole may have improved solubility, and dispersibility, thus decreasing side effects and time of treatment.


Find Patent Forward Citations

Loading…